OncoMatch/Clinical Trials/NCT07320508
Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
Is NCT07320508 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Epirubicin (E) for adenoid cystic carcinoma.
Treatment: Epirubicin (E) — This study is for patients with locally advanced sinonasal adenoid cystic carcinoma (SNACC), a rare and challenging cancer that tends to invade nerves and the skull base. The research aims to test a new precise treatment strategy. First, all participants will receive three sessions of "interventional chemotherapy" (transarterial chemoembolization) with the drug Epirubicin, which delivers high-dose chemotherapy directly to the tumor to shrink it as much as possible. About 4-6 weeks after the third session, doctors will use MRI scans to evaluate how well the tumor responded. Based on this response, patients will follow one of two personalized treatment paths: those whose tumors did not completely disappear will undergo surgery followed by radiotherapy; those whose tumors show complete disappearance on imaging will receive precise radiotherapy alone, potentially avoiding major surgery. This is a prospective, multicenter study. The main goals are to evaluate the safety and effectiveness of this response-adapted strategy and to see if it can improve outcomes for patients with this difficult-to-treat cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline (epirubicin)
Prior treatment with Epirubicin or any other anthracycline-based chemotherapy
Cannot have received: radiation therapy
Prior radiotherapy to the head and neck region
Cannot have received: chemotherapy
Administration of any other chemotherapy...within 4 weeks prior to study enrollment
Cannot have received: targeted therapy
Administration of...targeted therapy...within 4 weeks prior to study enrollment
Cannot have received: immunotherapy
Administration of...immunotherapy within 4 weeks prior to study enrollment
Lab requirements
Blood counts
Inadequate bone marrow function that does not meet the requirements for the planned treatment regimen
Kidney function
Inadequate kidney function that does not meet the requirements for the planned treatment regimen
Liver function
Inadequate liver function that does not meet the requirements for the planned treatment regimen
Inadequate liver, kidney, or bone marrow function that does not meet the requirements for the planned treatment regimen
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify